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Mevalonate kinase deficiency is an autosomal recessive
disorder characterized by recurring episodes of fever and
inflammation. Peripheral blood mononuclear cells from
mevalonate kinase deficiency patients secrete high levels
of IL-1β when stimulated with lipopolysaccharide (LPS)
due to the presence of hyperactive caspase-1. The molecu-
lar mechanism of mevalonate kinase deficiency-induced
caspase-1 activation remains unclear.
We artificially impaired isoprenoid biosynthesis in the
monocytic cells (THP-1) with simvastatin, after which
cells were stimulated with LPS. Simvastatin-treated THP-1
cells stimulated with LPS demonstrated enhanced release
of IL-1β. LPS enhanced transcription of IL-1β., whereas
simvastatin enhanced proteolytic activation of IL-1β. This
effect was mediated by phosphatidylinositol 3 kinase
(PI3K) and protein kinase B (PKB/c-Akt). In addition,
simvastatin-induced IL-1β secretion required the small
GTPase Rac1. Simvastatin treatment increased the levels
of biologically active GTP-bound Rac1 and inhibition of
Rac1 reduced simvastatin-mediated IL-1β secretion. Rac1
functioned upstream of PKB, since Rac1 inhibition abol-
ished the effect of simvastatin on PKB. Simvastatin-medi-
ated activation of the Rac1/PI3K/PKB pathway enhanced
IL-1β secretion through activation of caspase-1, since inhi-
bition of both Rac1 and PI3K blocked the release of active
caspase-1 subunits. The importance of Rac1 in meval-
onate kinase deficiency was confirmed when a specific
Rac1 inhibitor was shown to inhibit spontaneous IL-1β
release by mononuclear cells from mevalonate kinase
deficiency patients.
Together, these results demonstrate that Rac1, PI3K and
PKB are involved in simvastatin-induced secretion of IL-
1β through regulation of caspase-1 activity and that Rac1
is a potential new therapeutic target in mevalonate kinase
deficiency.
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